# A Study of LY2605541 in Participants With Type 2 Diabetes Mellitus

> **NCT01582451** · PHASE3 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 466 (actual)

## Conditions studied

- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** LY2605541
- **DRUG:** Insulin glargine

## Key facts

- **NCT ID:** NCT01582451
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-05
- **Primary completion:** 2013-05
- **Final completion:** 2013-12
- **Target enrollment:** 466 (ACTUAL)
- **Last updated:** 2018-04-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01582451

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01582451, "A Study of LY2605541 in Participants With Type 2 Diabetes Mellitus". Retrieved via AI Analytics 2026-07-17 from https://api.ai-analytics.org/clinical/NCT01582451. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*